Company intelligence / Profile preview

Isotopic Solutions Life Sciences

Vienna, Austria

Ownership: Private
Development stage: Other

Overview

ISOtopic Solutions produces stable isotope-labeled primary and secondary metabolic products using yeast cultures grown on synthetic media with >99% substitution of carbon atoms with ¹³C isotopes. The company's products are used as internal standards for mass spectrometry analysis in metabolomics research and provide superior analytical precision and accuracy.[3][5]

Modalities: Recombinant proteinSmall molecule
Industry: Non-Drug Biotech

Partnerships

Cambridge Isotope Laboratories (CIL) - partnership announced in 2022 to distribute stable isotope-labeled and unlabeled crude lipid yeast extracts[5]

Beyond the preview

Go deeper on Isotopic Solutions Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isotopic Solutions Life Sciences.

Explore the full profile